These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10213132)

  • 1. Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections.
    Nagai K; Hosaka H; Kubo S; Nakamura N; Shinohara M; Nonaka H
    J Gastroenterol; 1999 Apr; 34(2):275-81. PubMed ID: 10213132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection.
    Fang CT; Chen PJ; Chen MY; Hung CC; Chang SC; Chang AL; Chen DS
    J Hepatol; 2003 Dec; 39(6):1028-35. PubMed ID: 14642622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
    Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
    Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
    Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
    Hoff J; Bani-Sadr F; Gassin M; Raffi F
    Clin Infect Dis; 2001 Mar; 32(6):963-9. PubMed ID: 11247719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of hepatitis B virus/human immunodeficiency virus coinfection in a patient who achived hepatitis B surface antigen seroclearance after interferon therapy followed by antiretroviral therapy without developing immune reconstitution inflammatory syndrome].
    Mitsumoto F; Murata M; Ikezaki H; Ogawa E; Taniai H; Toyoda K; Otaguro S; Kainuma M; Okada K; Furusyo N; Hayashi J
    Kansenshogaku Zasshi; 2012 Nov; 86(6):763-7. PubMed ID: 23367852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.
    Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Jonas L; Meibohm A; Holder D; Schleif WA; Condra JH; Emini EA; Isaacs R; Chodakewitz JA; Richman DD
    JAMA; 1998 Jul; 280(1):35-41. PubMed ID: 9660361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections.
    van Rossum AM; Niesters HG; Geelen SP; Scherpbier HJ; Hartwig NG; Weemaes CM; Veerman AJ; Suur MH; de Graeff-Meeder ER; Slieker WA; Hop WC; Osterhaus AD; Burger DM; De Groot R
    J Pediatr; 2000 Jun; 136(6):780-8. PubMed ID: 10839877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy.
    Calisti G; Muhindo R; Boum Y; Wilson LA; Foster GM; Geretti AM; Bhagani S
    Trans R Soc Trop Med Hyg; 2015 Nov; 109(11):723-9. PubMed ID: 26386408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
    Ristig MB; Crippin J; Aberg JA; Powderly WG; Lisker-Melman M; Kessels L; Tebas P
    J Infect Dis; 2002 Dec; 186(12):1844-7. PubMed ID: 12447773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
    Santos EA; Sucupira MV; Arabe J; Gomes SA
    BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
    Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R
    Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic hepatitis B in HIV co-infected patients.
    Guan R
    Med J Malaysia; 2005 Jul; 60 Suppl B():52-6. PubMed ID: 16108174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy.
    Coffin CS; Mulrooney-Cousins PM; Osiowy C; van der Meer F; Nishikawa S; Michalak TI; van Marle G; Gill MJ
    J Clin Virol; 2014 Aug; 60(4):347-53. PubMed ID: 24881491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
    Gaglio PJ; Sterling R; Daniels E; Tedaldi E;
    Clin Infect Dis; 2007 Sep; 45(5):618-23. PubMed ID: 17682998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
    Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
    Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.